Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Patients With Stable Coronary Artery Disease

Dominick J. Angiolillo(University of Florida), Dietmar Trenk(Universitäts-Herzzentrum Freiburg-Bad Krozingen), Mark B. Effron(Eli Lilly (United States)), Fred Lipkin(Daiichi Sankyo (United States)), Marjorie E. Zettler(Eli Lilly (United States)), Wei Li, Paul A. Gurbel(Sinai Hospital), Joseph A. Jakubowski(Indiana Biosciences Research Institute), Paul T. Vaitkus(Daiichi Sankyo (United States))
Journal of the American College of Cardiology
December 12, 2013
10.1016/j.jacc.2013.11.032
Cited by 92

Related Papers

Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events
|New England Journal of Medicine|2013|825
Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38
|Circulation|2008|757
Ischemia and No Obstructive Coronary Artery Disease (INOCA)
|Circulation|2017|745
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
|New England Journal of Medicine|2013|651